NCT06148272

A Study of LY3971297 in Healthy Participants

A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 225 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.

Conditions

• Healthy
• Obesity
• Hypertension

Interventions

Type	Name	Description
DRUG	LY3971297	Administered SC
DRUG	Placebo	Administered SC
DRUG	LY3971297 IV	Administered IV

Timeline

• Start date: 2023-12-07
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2023-11-28
• Last updated: 2026-02-23

Locations

7 sites across 3 countries: United States, Japan, Singapore

Regulatory

• FDA-regulated drug study